Cambridge Cognition Limited
Cambridge Cognition is a digital neuroscience company developing software products to better understand, detect and treat brain health conditions. Our cognitive technologies are used to accelerate the research and development of new treatments, enhance understanding of the brain and accurately assess cognitive health in patients worldwide.
|Address:||Turnbridge Court, Turnbridge Lane, Bottisham|
|Membership type:||Corporate 21-50 (£500+VAT pa)|
Cambridge Cognition is the leading provider of cognitive assessment software for academic research, healthcare provision and clinical trials. Developing global solutions to improve mental wellbeing.
Our cognitive assessment software, powered by CANTAB technology, has been highly validated by over 2,000 peer-review publications.
CANTAB touchscreen neuropsychological tests are used by:
- Academic researchers in studies of cognition
- Clinical researchers in the pharmaceutical industry, to further knowledge of cognitive function
- Physicians to improve the monitoring, management and maintenance of cognitive health and wellbeing.
Our product ranges include:
The digital neuroscience company Cambridge Cognition Holdings PLC (AIM: COG) is pleased to announce a planned new software product to assess mental health and wellbeing at work, CANTAB BrainHealth™.
21 June 2018Read in full
The digital neuroscience company Cambridge Cognition Holdings PLC (AIM: COG), which develops and markets digital solutions to assess brain health, is pleased to announce a new strategic collaboration and partnership with the University of Bristol to accelerate the development of novel brain health products.
7 June 2018Read in full
Cambridge Cognition Holdings PLC, (AIM: COG) the digital neuroscience company which develops and markets software products to assess brain health, is pleased to announce that its CANTAB Recruit software is now established in two major Phase III trials with one of the early adopters increasing its contract value twenty-four fold in the first year of use, totalling over £1.2 million.
11 April 2018Read in full
The digital neuroscience company Cambridge Cognition Holdings PLC, (AIM: COG) which develops and markets software products to improve brain health, is pleased to announce the award of a major new pharmaceutical clinical trial contract and a Digital Health Catalyst grant from Innovate UK.
29 March 2018Read in full
Cambridge Cognition shows its groundbreaking mental health wearable Cognition Kit™ for the first time at the Neurotech Investing Conference in Boston this week.
7 April 2016Read in full
Cambridge Cognition Holdings plc, a specialist in the development and marketing of computerised tests for detection and monitoring of neuropsychological disorders, is pleased to announce that it has made significant progress with its commercial operations and expects to end the year with three new major pharmaceutical clinical trial contracts totalling US$4.5m.
24 November 2015Read in full
Three decades ago two emerging neuroscientists, Barbara Sahakian and Trevor Robbins from University of Cambridge, received a grant to fund their development of the Cambridge Neuropsychological Automated Test Battery or CANTAB™.
9 October 2015Read in full
Reliable cognitive measures for patients with Alzheimer's disease are essential when testing potential new drug interventions. The high attrition rate in Alzheimer’s disease clinical trials highlights the need for more sensitive analytical tools to be used throughout the drug development process.
21 May 2015Read in full
Cambridge Cognition today announces that sales of its Cantab Connect CTIS-Abuse Liability have exceeded £1 million ($1.5 million) in its first nine months from launch.
14 April 2015Read in full